BioLine Rx | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioLine Rx | 6-K: Report of foreign private issuer (related to financial reporting)
BioLine Rx | 6-K: Report of foreign private issuer (related to financial reporting)
BioLine Rx | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioLine Rx | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioLine Rx | 6-K: Report of foreign private issuer (related to financial reporting)
BioLine Rx | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioLine Rx | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioLine Rx | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioLine Rx | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioLine Rx | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioLine Rx | 6-K: Report of foreign private issuer (related to financial reporting)
BioLine Rx | 424B5: Prospectus
BioLine Rx | 20-F/A: Registration statement / Annual report / Transition report (Amendment)
BioLine Rx | 20-F: FY2023 Annual Report
BioLine Rx | 6-K: Report of foreign private issuer (related to financial reporting)
BioLine Rx | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioLine Rx | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioLine Rx | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
BioLine Rx | EFFECT: Others
No Data
No Data